 | |  | |  | |  | |  | |  | |  | |  |
| IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Int J Clin Exp Med 2013;6(9):747-756
Original Article
Symptom improvement after helicobacter pylori eradication in patients with
functional dyspepsia-A multicenter, randomized, prospective cohort study
Sanping Xu, Xueming Wan, Xiaolan Zheng, Yali Zhou, Zhiqiang Song, Minghu Cheng, Yiqi Du, Xiaohua Hou
Division of Gastroenterology, Union Hospital of Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China;
People’s Hospital of Peking University, Peking, China; ZhongShan Hospital of ZhongShan University, GuangZhou, China; ChangHai
Hospital, Second Military Medical University, Shanghai, China
Received August 3, 2013; Accepted September 16, 2013; Epub September 25, 2013; Published September 30, 2013
Abstract: Objective: To observe the improvement of functional dyspepsia (FD) after helicobacter pylori (HP) eradication in FD patients.
Methods: 644 FD patients were recruited of whom 585 completed follow up. They were divided into postprandial distress syndrome
(PDS) group and epigastric pain syndrome (EPS) group. Patients with HP infection were randomly allocated into eradication group and
non-eradication group. Patients in the eradication group were randomly assigned into two groups and treated with triple therapy and
sequential therapy, respectively. Patients in non-eradication group and HP non-infection group were treated with Domperidone (PDS
patients) or Talcid (EPS patients). Clinical symptoms were evaluated. Results: When compared with patients with unsuccessful HP
eradication and without eradication, significant improvement in symptoms was found at 8 w, 12 w, and 26 w in patients with successful
HP eradication in EPS group (P < 0.05). However, in PDS group, improvement in symptoms was comparable among patients expect at
26 w after successful HP eradication (P < 0.05). Therapeutic efficacy in patients without HP eradication was poorer than that in HP
negative patients in EPS group (P < 0.05), while in PDS group, symptoms were relived at 26 w and 52 w (P < 0.05). Conclusions: HP is
one of pathogenic factors of FD and HP eradication may benefit FD patients, regardless therapeutic regimes, especially in EPS
patients. (IJCEM1308006).
Keywords: Epigastric pain syndrome, functional dyspepsia, helicobacter pylori eradication, helicobacter pylori infection, postprandial
distress syndrome, sequential-therapy, triple-therapy
Address correspondence to: Xiaohua Hou, Division of Gastroenterology, Union Hospital of Tongji Medical college, Huazhong
University of Science and Technology, Wuhan, China. E-mail: houxiaohua414@yeah.net; 1989596@hust.edu.cn; Yali Zhou, Division of
Gastroenterology, People’s Hospital of Peking University, Peking, China. E-mail: Liyazhou@medmail.com.cn
Original Article
Symptom improvement after helicobacter pylori eradication in patients with
functional dyspepsia-A multicenter, randomized, prospective cohort study
Sanping Xu, Xueming Wan, Xiaolan Zheng, Yali Zhou, Zhiqiang Song, Minghu Cheng, Yiqi Du, Xiaohua Hou
Division of Gastroenterology, Union Hospital of Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China;
People’s Hospital of Peking University, Peking, China; ZhongShan Hospital of ZhongShan University, GuangZhou, China; ChangHai
Hospital, Second Military Medical University, Shanghai, China
Received August 3, 2013; Accepted September 16, 2013; Epub September 25, 2013; Published September 30, 2013
Abstract: Objective: To observe the improvement of functional dyspepsia (FD) after helicobacter pylori (HP) eradication in FD patients.
Methods: 644 FD patients were recruited of whom 585 completed follow up. They were divided into postprandial distress syndrome
(PDS) group and epigastric pain syndrome (EPS) group. Patients with HP infection were randomly allocated into eradication group and
non-eradication group. Patients in the eradication group were randomly assigned into two groups and treated with triple therapy and
sequential therapy, respectively. Patients in non-eradication group and HP non-infection group were treated with Domperidone (PDS
patients) or Talcid (EPS patients). Clinical symptoms were evaluated. Results: When compared with patients with unsuccessful HP
eradication and without eradication, significant improvement in symptoms was found at 8 w, 12 w, and 26 w in patients with successful
HP eradication in EPS group (P < 0.05). However, in PDS group, improvement in symptoms was comparable among patients expect at
26 w after successful HP eradication (P < 0.05). Therapeutic efficacy in patients without HP eradication was poorer than that in HP
negative patients in EPS group (P < 0.05), while in PDS group, symptoms were relived at 26 w and 52 w (P < 0.05). Conclusions: HP is
one of pathogenic factors of FD and HP eradication may benefit FD patients, regardless therapeutic regimes, especially in EPS
patients. (IJCEM1308006).
Keywords: Epigastric pain syndrome, functional dyspepsia, helicobacter pylori eradication, helicobacter pylori infection, postprandial
distress syndrome, sequential-therapy, triple-therapy
Address correspondence to: Xiaohua Hou, Division of Gastroenterology, Union Hospital of Tongji Medical college, Huazhong
University of Science and Technology, Wuhan, China. E-mail: houxiaohua414@yeah.net; 1989596@hust.edu.cn; Yali Zhou, Division of
Gastroenterology, People’s Hospital of Peking University, Peking, China. E-mail: Liyazhou@medmail.com.cn
